Issue 5, 2018

Towards an MMP-2-activated molecular agent for cancer imaging

Abstract

Matrix metalloproteinases (MMPs) have been identified as biomarkers for cancer, offering prognostic potential; however, non-invasive detection protocols are currently lacking. Herein, we describe the synthesis of a DOTA-containing peptide sequence that can be radiolabelled easily with 68Gallium or can be incorporated with gadolinium for possible MRI applications with clear selectivity for MMP-2 over other members of the MMP family, giving MMP-2 selective cleavage of the labelled peptides.

Graphical abstract: Towards an MMP-2-activated molecular agent for cancer imaging

Supplementary files

Article information

Article type
Paper
Submitted
21 Aug 2017
Accepted
04 Dec 2017
First published
04 Dec 2017

Dalton Trans., 2018,47, 1530-1534

Towards an MMP-2-activated molecular agent for cancer imaging

S. Cowell, L. Carroll, I. Lavdas, E. O. Aboagye and R. Vilar, Dalton Trans., 2018, 47, 1530 DOI: 10.1039/C7DT03108D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements